Search research articles
Contact Us
Filters
Showing results (91-100 of 102) with videos related to
Page
of 11
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2025
Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI
Barbara W Trautner, Nicolás W Cortés-Penfield, Kalpana Gupta, et al.
The Lancet. Infectious Diseases
|
April 9, 2018
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2025
Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI
Barbara W Trautner, Nicolás W Cortés-Penfield, Kalpana Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2025
Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Duration of Antibiotics for Complicated UTI
Barbara W Trautner, Nicolás W Cortés-Penfield, Kalpana Gupta, et al.
Cell Reports
|
September 29, 2021
Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity
Maria Vono, Angela Huttner, Sylvain Lemeille, et al.
The Lancet. Microbe
|
May 11, 2022
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
Eleonora Vianello, Patricia Gonzalez-Dias, Suzanne van Veen, et al.
The Lancet. Infectious Diseases
|
August 8, 2015
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Angela Huttner, Julie-Anne Dayer, Sabine Yerly, et al.
The Journal of Antimicrobial Chemotherapy
|
January 21, 2014
An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units
Gloria Wong, Alexander Brinkman, Russell J Benefield, et al.
Frontiers in Immunology
|
November 29, 2023
Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts
Patrícia Conceição Gonzalez Dias Carvalho, Thiago Dominguez Crespo Hirata, Leandro Yukio Mano Alves, et al.
The Lancet. Infectious Diseases
|
February 28, 2017
Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial
Angela Huttner, Christoph Hatz, Germie van den Dobbelsteen, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 102) with videos related to
Sort By:
Page
of 11
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2025
Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI
Barbara W Trautner, Nicolás W Cortés-Penfield, Kalpana Gupta, et al.
The Lancet. Infectious Diseases
|
April 9, 2018
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2025
Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI
Barbara W Trautner, Nicolás W Cortés-Penfield, Kalpana Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2025
Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Duration of Antibiotics for Complicated UTI
Barbara W Trautner, Nicolás W Cortés-Penfield, Kalpana Gupta, et al.
Cell Reports
|
September 29, 2021
Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity
Maria Vono, Angela Huttner, Sylvain Lemeille, et al.
The Lancet. Microbe
|
May 11, 2022
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
Eleonora Vianello, Patricia Gonzalez-Dias, Suzanne van Veen, et al.
The Lancet. Infectious Diseases
|
August 8, 2015
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Angela Huttner, Julie-Anne Dayer, Sabine Yerly, et al.
The Journal of Antimicrobial Chemotherapy
|
January 21, 2014
An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units
Gloria Wong, Alexander Brinkman, Russell J Benefield, et al.
Frontiers in Immunology
|
November 29, 2023
Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts
Patrícia Conceição Gonzalez Dias Carvalho, Thiago Dominguez Crespo Hirata, Leandro Yukio Mano Alves, et al.
The Lancet. Infectious Diseases
|
February 28, 2017
Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial
Angela Huttner, Christoph Hatz, Germie van den Dobbelsteen, et al.
Page
of 11